drugset / Trial / NCT01570049

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

NCT01570049

Phase 3 Unknown 100 enrolled Shandong Lanjin Pharmaceuticals Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether bendamustine HCl for injection is safe and effective in the treatment of Rituximab refractory or relapsed B-cell indolent lymphoma.

Timeline

Start
2010-04
Primary completion
2012-09
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 120 mg/m2 Intravenous